ImmuPharma and Incanthera extend exclusivity period for Nucant agreement

Specialist drug discovery and development company ImmuPharma updated the market on its clinical development collaboration agreement for its 'Nucant' cancer programme on Monday, with specialist oncology development partner Incanthera.

The AIM-traded firm had announced on 7 December that, alongside Incanthera, it was making “good progress” in finalising the 'definitive licence agreement'.

It had been agreed between both companies to extend the exclusivity period - which was initially granted to 31 December - to 31 March, in order to finalise the remaining parts of the agreement.

ImmuPharma said it now envisaged that the agreement would be finalised in the first quarter of 2019 and as such, a further update on the collaboration would be announced in due course.

“We are working diligently with Incanthera's management team to finalise the last remaining parts to the 'definitive licence agreement', and look forward to updating the market and shareholders in the first quarter of 2019,” said ImmuPharma chief executive officer Dimitri Dimitriou.